eligibility_summary
Adults 18–75 with CD19+ or CD70+ B‑cell NHL (DLBCL, tFL, PMBCL, MCL, transformed indolent) that is relapsed/refractory, ≥1 measurable lesion, ECOG 0–3, life expectancy >12 wks, adequate organs, prior auto‑HSCT allowed, washout 2–3 wks, failed/relapsed after CAR‑T, contraception, COVID‑19 negative. Exclude: product allergy, other cancers, grade II–IV GVHD/anti‑GVHD, recent gene therapy, active infection (HBV/HCV/HIV/syphilis), NYHA III/IV, >grade 1 toxicities, seizures/CNS disease/CNS lymphoma, breastfeeding, investigator risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: dualCAR-NK19/70, an allogeneic, cord blood–derived chimeric antigen receptor natural killer (CAR NK) cell therapy administered IV. Mechanism: NK cells are gene-modified to express two CARs that recognize CD19 and CD70 on B‑cell malignancies, CAR engagement activates NK cytotoxic signaling to lyse target cells, with dual targeting aiming to reduce antigen escape. Targets: malignant B cells in r/r B‑cell NHL (DLBCL, tFL, PMBCL, MCL) expressing CD19 and/or CD70. Pathways: CD19 and CD70 antigen pathways, CAR-activated, MHC‑independent NK effector killing. Study goal: define safety/MTD/RP2D and efficacy.